Nucleai
Cris De Luca currently serves as a Partner at Sanofi Ventures, where responsibilities include leading global venture capital investments in Digital Health, AI, and Data Science Innovation. Since June 2020, Cris has also held board member positions at Carbon Health, Empatica, Nucleai, Medisafe®, and Click Therapeutics, Inc., along with board observer roles at Omada Health and Aetion. Cris's prior experience includes serving as an investor at Science 37 and a board observer at Common Sensing. Educational qualifications include a Master of Science in Computer Information Systems from Boston University, completion of the MIT Enterprise Invest Venture Capital Program, and a Bachelor of Science in Business Administration with a focus on ECommerce from Suffolk University.
This person is not in the org chart
This person is not in any offices
Nucleai
7 followers
Nucleai is a spatial biology company that has developed an AI-powered platform to enhance drug development and improve patient outcomes. Nucleai’s platform leverages unique tissue datasets to produce insights into cancer biology, increasing clinical trial efficacy and improving patient care. Nucleai works with leading pharmaceutical companies,licensing its research platform for internal use, and collaborating in biomarkers discovery projects.